BridgeBio CAO Sells Shares; Company Posts Positive Phase 3 Data and Prices Convertible Notes
BridgeBio Pharma Chief Accounting Officer Maricel Apuli reported two recent stock transactions in mid-February 2026, including a sale and a tax-withholding disposition. The company concurrently disclosed positive Phase 3 data for oral infigratinib in achondroplasia and completed a $550 million private offering of convertible senior notes due 2033. …